PPAR{delta} Reprograms Glutamine Metabolism in Sorafenib-Resistant HCC

This study provides novel insight into the mechanism underlying sorafenib resistance and a potential therapeutic strategy targeting PPAR in advanced hepatocellular carcinoma. Mol Cancer Res; 15(9); 1230–42. ©2017 AACR.

Source: Molecular Cancer Research - August 31, 2017 Category: Cancer & Oncology Authors: Kim, M.-J., Choi, Y.-K., Park, S. Y., Jang, S. Y., Lee, J. Y., Ham, H. J., Kim, B.-G., Jeon, H.-J., Kim, J.-H., Kim, J.-G., Lee, I.-K., Park, K.-G. Tags: Metabolism Source Type: research